Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

Nicotine dependence is common among drug and alcohol dependent patients. This multi-site trial evaluated the effectiveness of smoking-cessation treatment with transdermal nicotine patch replacement (SC) as an adjunct to treatment-as-usual for illicit substance abuse (TAU). Cigarette smokers from five methadone-maintenance clinics and two drug and alcohol dependence treatment programs were randomly assigned to receive either SC as an adjunct to usual care or TAU. SC consisted of 1 week of group counseling before the target quit date and 8 weeks of group counseling plus transdermal nicotine patch replacement treatment after the target quit date.

CTN Protocol ID: 
CTN-0009
DSMB ID: 
NIDA-CTN-0009
ClinicalTrials.gov ID: 

Principal Investigator(s)

John Rotrosen, M.D.
Professor
NYU School of Medicine
Department of Psychiatry
One Park Avenue, 8th Floor
New York, NY 10016
john.rotrosen@nyumc.org

Static CTPS

Participating Sites